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Abstract
The phenomenon of autoimmunity develops as a result of the triggering factor released by
damaged cells. This leads to an infiltration of CD4+ cells involved in stimulating the effector
cells  cytotoxicity  and  stimulating  the  humoral  response.  One  of  the  most  common
autoimmune disorders  are  autoimmune thyroid  diseases,  including Hashimoto's  thyroiditis
and Graves's diseases. Helper T lymphocytes, which are divided into Th1, Th2, Tregs, and the
relatively new groups Th17, Th22, and Th9, are involved in the pathogenesis of AITD. CD4+
cell  subtypes  mature  and  differentiate  by  specific  transcription  factors  and  in  a  specific
interleukin environment.  Not only are  Th1 and Th2 cells  involved in the development  of
AITD, but also Th17, Th22, and Th9 lymphocytes and their correlation to Tregs lymphocytes.
The plasticity of the CD4+ cells is very important, affecting the balance between these cells,
as  well  the  factors  modulating  their  phenotypic  variability.  Patients  with  AITD  have  an
increased percentage of Th17, Th22, and Th9 cells as well as defective function of Tregs
lymphocytes. The balance between Th17 cells (and also other cytotoxic T cells) and Treg cells
is also very important. Understanding the role of CD4 cells in the pathogenesis of AITD may
be  important  not  only  for  the  development  of  the  knowledge,  but  also  for  determining
therapeutic targets.
Key words: CD4+ T cell; Th lymphocytes; Treg lymphocytes; autoimmune thyroid disease 
Introduction
In recent years, the hypothesis regarding the initiation triggers, the initiation itself, and the
course  of  the  autoimmunity process  has  changed.  From Burnet's  self-non-self  theory [1],
through the infection non-self  theory by Janeway [2,  3] (according to  which the antigen-
presenting cells [APSs] react with the pathogen-associated molecular patterns [PAMPs], e.g.
liposaccharide  [LPS]  and  only  their  presence  initiates  the  immune  response),  to  Polly
Matzinger’s danger theory [4]. According to the latter theory, an immune response will be
induced only if there is an alarm signal released by the endogenous cells that are damaged
(danger/damage-associated molecular patterns [DAMPs]), so the response is a consequence of
the appearance of a sent danger signal, whether it comes from the cell itself or from a foreign
cell [5]. Among the growing group of already known danger signals (DAMPs) the following
should be noted: extracellular nucleic acids, ATP, heat shock proteins, uric acid, and HMGB1
protein, among others.
Thyroid follicular cells have Toll-like receptors (TLRs) that respond to PAMPs and DAMPs.
These triggers activate the immune response: CD4+ cells influx, secretion of proinflammatory
cytokines, and ultimately cell damage and apoptosis [6].
Autoimmune  thyroid  diseases  (AITDs)  –  of  which  the  main  representatives  are  chronic
lymphocytic thyroiditis (Hashimoto’s thyroiditis, HT) and Graves's disease (GD) – are the
organ-specific autoimmune diseases characterized by a breakdown of self-tolerance to thyroid
antigens [7]. Although the AITDs are the most common autoimmune diseases, we still do not
know enough about the triggers of autoimmune responses to thyroid antigens: thyroglobulin
(Tg),  thyroid  peroxidase  (TPO),  and thyrotropin  receptor  (TSHR).  There  is  widespread
consensus  that,  for  the  occurrence  of  the  thyroid  cell  self-destruction,  there  must  be  a
coincidence of genetic predisposition and an environmental factor.  Many genes,  including
TSHR, TG, HLA-DR3, CTLA-4, and PTPN22, contribute to the predisposition of AITD [8–
10]. 
In recent years, our knowledge about the autoimmune process has expanded significantly.
From the basic information on Tc, Th1, and Th2 lymphocytes involved in the destruction or
stimulation of the thyroid gland, we know much more about the autoimmune response in the
thyroid gland. The initial Th1/Th2 paradigm in the AITD process has been changed to the
balance and interaction of the relatively new Th17 and Treg lymphocytes, as well as Th22 and
Tfh [9]. In order to learn about the importance and interdependence of particular subtypes of
CD4+ cells (including Th1, Th2, Th17, and Treg lymphocytes) in the pathogenesis of AITD,
we  would  like  to  present  the  current  knowledge  on  their  differentiation,  division  into
subtypes, and characteristic functions.
Subtypes and differentiation of the CD4+T cells
The CD4+ cells are created in the thymus from the naïve CD4+ cells and then appear in the
peripheral lymphoid tissues as mature naïve T cells [11]. These cells, with the participation of
distinct  cytokines  and  transcription  factors,  are  differentiated  into  particular  CD4+T cell
subtypes  [12].  Obviously,  the  process  of  differentiating  mature  naïve  CD4+  cells  into
subtypes of CD4+Th cells is preceded by activation of 2 (at least) or 3 (preferably) signals.
The  first  signal  is  derived  from  antigen-presenting  cells,  which  present  antigen-derived
peptides in the context of the major histocompatibility complex MHC class II molecules to
the T-cell receptor (TCR) [13]. The second signal is the result of combining co-stimulating
molecules. The cytokine receptor stimulation makes the third signal [13,14].
The  regulation  of  the  formation  and  differentiation  of  individual  CD4+  cell  subtypes
participate in the noncoding RNA chains (ncRNAs), whose disturbed expression is closely
related to the pathogenesis of AITD [15].  
What is very important (but is not our focus) is the fact that in the thymus, T lymphocytes
mature under a multistage process of positive selection (in the thymic cortex) and negative
selection (through the epithelial cells in the medulla of thymus) [9]. In this process some of
the leaving the thymus lymphocytes react through the activation initiated by self-antigens; it is
one of the triggers of autoimmunity.
The resulting CD4+ cells divide into helper T lymphocytes (Th) and regulatory lymphocytes
(Treg).
Th cell subtypes
The main surface molecule of Th cells that identifies them is CD4 (cluster of differentiation
4). This glycoprotein is a Th cell coactivator, and its major ligand is MHC class II molecule.
The  binding  of  the  second-class  MHC  molecule  present  on  the  surface  of  the  antigen-
presenting cell with CD4 is the second signal of Th cell activation. 
The  cells  including  CD4  on  their  surface  are  involved  in  the  regulation  of  the  immune
response,  either  supporting  it  or  inhibiting  it.  Depending  on  these  2  functions,  they  are
respectively called helper and regulatory (suppressor). CD4+ cells are divided into 4 main
groups:  Th1,  Th2,  Th17,  and  Treg.  Besides  them,  the  following  are  distinguished:  Tfh
(follicular helper), Th9, and Th22 cells [9]. However, it is uncertain whether these CD4+ cell
types constitute separate Th cell lineages or they are variants of major type cells, but they
certainly display distinctive features [16].
Th1 cells
Th1 cells are developed from Th0 in the IL-12 and interferon-γ (IFN-γ) environment with the
participation of the transcription factors T-bet (T box expressed in T cells) and STAT1 and
STAT4 (signal traducer and activator of transcription) [14,17,18,19].
The most powerful Th1-polarizing cytokine is IL-12, which is produced by myeloid dendritic
cells  (DCs) [19]. IL-12 not only induces the differentiation of Th1 lymphocytes,  but also
increases their activity and proliferation, and stimulates the secretion of IFN-γ and  tumour
necrosis factor-α (TNF-α). IL-12 is  also important because it  plays  a negative role in the
development of autoimmune diseases, and the monoclonal antibody against the p40 subunit of
IL-12 is used in the treatment of psoriasis [14]. 
Th1 cells also play a decisive role in promoting a cell-type response. This is mainly done by
IL-2, lymphotoxin α (LT-α), and IFN-γ, which are produced by Th1 [15, 20]. The activated
CD8+  cytotoxic  cells,  stimulated  by  these  cytokines,  are  primarily  responsible  for  the
destruction of cells, including thyrocytes in HT.
Th2 cells
In order to obtain the second group of Th2 cells, both IL-2 and IL-4 must be present. The
major product of Th2 lymphocytes, IL-4, is also a critical inducer of Th2 cell differentiation
[14, 16]. Th2 lymphocytes produce IL-4, IL-5, IL-10, and IL-13, which are factors in the B-
lymphocyte growth and differentiation. Thus, their primary function is to promote a humoral
immune  response.  Th2  cells  play  a  major  role  in  immune  defence  against  extracellular
parasites and development of an allergic reaction [20]. Interestingly, interleukins secreted by
Th2 cells inhibit the production of inflammatory cytokines, such as IFN-γ. It was found in
animal  models  that  IL-4  had  a  protective  effect  on  the  development  of  the  autoimmune
diseases, which will be described later [7].
As in the Th1 lineage, as well as cytokines, transcription factors play an important role in the
differentiation of Th2 lymphocytes. STAT6 (signal transducer and activator of transcription 6)
and GATA-3 are  the  main  transcription  factors  for  the  Th2 subtype  [21,22].  STAT6 is  a
downstream effector of IL-4, while GATA-3 is associated with the promotion of the secretion
of Th2 cell cytokines such as IL-4, IL-5, and IL-13, thereby promoting a humoral response
[23].
Th17 cells
Like Th1 and Th2 lymphocytes, Th17 cells develop from naive CD4 cells (1 out of 4 cell
groups: Th1, Th2, Th17, and iTregs) [1410,1612].
Th 17 cells  were described in 2003 by Aggarwal  [24].  The discovery of this  lymphocyte
subtype was initiated and named after the identification of IL-17A in 1993 (by Rouvier et al.)
[25, 26].
They  have  been  described  as  producing  IL-17A,  IL-17F  [27],  and  IL-22  [28],  which
distinguishes them from Th1 and Th2 cells, which do not produce these cytokines [29]. Th17
also produces IL-21; however, it might be secreted by other Th cells [16]. Differentiation of
naive T cells into Th17 cells is mainly induced in the environment of  transforming growth
factor-beta (TGF-β) and IL-6, but other cytokines also contribute, such as IL-1β, IL-21, IL-23,
and TNF-α [30–32].
In addition, transcription factors contribute to the formation (differentiation) of Th17 from
naive T cells. The most important of them are retinoic acid receptor-related orphan receptor
(RORγt) and STAT3 and equally important STAT5, interferon regulatory factor-4 (IRF-4), and
basic leucine zipper transcription factor ATF-like (BATF), Runt-related transcription factor-1
(Runx-1), and the aryl hydrocarbon receptor (Ahr) [29, 33]. RORγt remains the characteristic
transcription factor allowing the identification of Th17 cells.
Dealing with Th17 cells, the existing division into non-pathogenic and pathogenic Th17 cells
should  be noted.  The non-pathogenic Th17 cells  naturally occur  in  the gut,  and they are
responsible  for  maintaining  the  homeostatic  microbiota  and  fighting  against  pathogenic
microbes  [34].  They  have  no  autoreactive  features.  Unlike  non-pathogenic  ones,  the
pathogenic  Th17  cells  arise  in  the  presence  of  IL-23 and are  mainly responsible  for  the
development of autoimmune reactions to self-antigen [34, 35].
Tfh cells
As effector cells, the Tfh cells can enter tissues and mediate inflammation. Additionally, this
population develops into memory cells residing in the lymph nodes and the spleen. These
effector/memory cells are distinct states of each type: Th1, Th2, Th17, and Tregs. Their main
function is to help B lymphocytes to produce antibodies, especially in the germinal centres, so
they  are  called  follicular  helper  cells  Tfh  [16].  These  cells  mediate  both  helping  B
lymphocytes and switching Ig classes (help and class switching).
Tfh cell differentiation takes place in several steps and requires the presence of IL-6, IL-12,
IL-21, and activin A signalling [36]. Their main transcription factor is B cell lymphoma 6
(Bcl6),  which  limits  Th1  differentiation  and  supports  Tfh  cell  differentiation  [37].  Bcl-6
controls expression of most of genes related to Tfh cell differentiation, but it is not sufficient
for the development of these cells. Equally important is the expression of transcription factor
Maf, also known as proto-oncogene c-Maf (c-Maf), which induces the production of IL-21
necessary for the formation of Tfh cells [36].
It is uncertain whether Tfh is an independent and individual CD4 lineage or an effector state
of each of the 3 CD4 cell lineages. Tfh cells produce both IL-4 and IFN-γ as do Th1 and Th2,
but we do not know if Tfh cells acquired the ability to produce IL-4 and IFN-γ, or whether
Th1 and Th2 acquire the features of Tfh cells. Pearce's studies showed that Tfh cells can arise
from Th2 cells, which acquire the Tfh phenotype after antigen activation [16]. Thus, it  is
unknown  whether  this  is  a  separate  CD4+  cell  lineage.  However,  studies  confirm  that
dysregulation of Tfh cell differentiation and function may be associated with the development
of autoimmunity [37]. 
Th9 cells
Relatively recently,  Veldhoen et  al.  (2008) described a subpopulation of CD4 + cells  that
produce a lot of IL-9, and less IL-10 and IL-23 [38]. Primarily the product of these cells, IL-9
was discovered in 1989 by Van Snick et al. [39]. However, it was uncertain which of the
known immune system cells produce the greatest amount of this cytokine, especially if it is
secreted by several types of cells [40]. Initially, it was considered a product of Th2 cells. Just
13 years ago it was disclosed that the Th lymphocytes producing IL-9 in such large numbers
do not have the ability to secrete cytokines typical of other known Th cell lines: IL-4, IL-5,
and  IL-13  of  Th2;  IFN-γ  for  Th1;  and  IL-17α  for  Th17.  They  also  lack  the  specific
transcription factors T-bet for Th1, GATA-3 for Th2, ROR-γt for Th17, and FoxP3 for Treg.
Thus,  they  constitute  a  different  T-lymphocytes  subpopulation  that  was  named  Th9
lymphocytes [41]. These cells develop from naive CD4+ T cells in the presence of IL-4 and
TGF-β, which inhibit Th2 cells [40].
The transcription key factor for Th9 lineage development is PU.1, which is one of the ETS
family transcription factors (E-26), as well as IRF-4. The latter is induced by STAT6, which is
activated by IL-4. Thus, the presence of STAT6, PU.1, and IRF-4 is characteristic of CD4+
Th9 cells. Th9 cells are involved in immunity to parasites, cancer (IL-9 is crucial in inhibiting
tumour  growth),  and  allergic  diseases  (mainly  asthma)  [14,41].  Th9-secreted  IL-9  has  a
pleiotropic effect,  but  one of  its  functions is  to  stimulate  Th17 proliferation and increase
inflammation.  In this  way Th9 cells  may be involved in  the development  of autoimmune
diseases.
Th22 cells
A year after the description of Th9 cells, a new subset of IL-22-producing CD4+ cells was
discovered (Trifari, 2009) [42]. Like the previous Th cell subtypes, Th22 cells also develop
from naive CD4+ T cells, and their differentiation occurs in the presence of Il-6 and TNF-α
[43]. A lot of earlier data show that IL-22 (described in 2000) is produced by activated T cells
including Th22 cells,  Th17 cells,  Th1 cells,  and the other lymphoid cells.  Initially it  was
thought that IL-22 was a Th1-associated cytokine. After the discovery of Th17 cells, these
lymphocytes  were considered crucial  in  the production of IL-22.  In subsequent  studies  it
turned out that there was a separate lineage of Th cells, which produce IL-22 without IFN-γ,
IL-4, and IL-17α, and its differentiation depends on the transcription factor aryl hydrocarbon
receptor  (AHR).  AHR is  a  key feature  of  Th22  cells.  Engagement  of  AHR leads  to  the
increase of IL-22 production and the decrease of IL-17 expression [43].  IL-22 expression
requires AHR. Interestingly,  the receptors for IL-22 (IL-22R) are expressed in skin, small
intestine, liver, and kidney but not in the immune system [9].
The main function of IL-22 is a regulation of various innate mechanisms to eliminate invasive
pathogens  attacking  epithelial  cells.  IL-22  has  been  linked  to  skin  homeostasis  and
inflammation [14, 43].
Th22 cells, through secreted IL-22, also exert a negative effect, i.e. they are closely associated
with  various  diseases,  including  autoimmune  diseases  (psoriasis,  rheumatoid  arthritis,
inflammatory bowel diseases, SLE, systemic sclerosis, and others) [16, 44, 45].
Regulatory T-cell subtypes
Regulatory lymphocytes (Tregs), described in the 1970s, are characterized by inhibition of the
immune  response.  Tregs  maintain  homeostasis  and  prevent  autoimmune  responses  by
targeting T cells, dendritic cells, macrophages, mast cells, and B cells [46]. Their action is
direct, from cell to cell, or through secreted cytokines such as TGF-β and IL-10. What makes
Tregs a distinctive separate group of CD4 +cells is high constitutive expression of the surface
marker  CD25,  i.e.  IL-2  receptor  α  chain,  cytotoxic  T-lymphocytes  associated  protein  4
(CTLA-4), and glucocorticoid-induced tumour necrosis factor-related protein (GITR), as well
as the expression of the specific transcription factor forkhead box protein 3 (FoxP3) [47]. The
FoxP3 mutation is responsible for the development of IPEX syndrome (immunodeficiency,
polyendocrinopathy and enteropathy, X-linked syndrome).
Likewise, the CD4+ helper cell type, Treg lymphocytes also comprise a heterogeneous group.
CD4+CD25highFoxP3  cells  that  are  produced  in  the  thymus  are  called  natural  (nTreg)  or
thymus-derived Treg cells [11, 14]. The nTregs, completely differentiated in the thymus, can
recognize self-antigens and inhibit the activation, proliferation, and synthesis of cytokines by
effector lymphocytes [11].
The second  group of  Tregs  lymphocytes  are  the  cells  that  after  contact  with  the  antigen
develop and differentiate peripherally, beyond the thymus, so they are called inducible Tregs
(iTregs) or peripheral differentiated (pTregs) [8, 11]. The iTreg cells differ from nTregs in the
mechanism of immunosuppressive action, which is mediated by the secretion of TGF-β and
IL-10 cytokines,  but  not  directly  from cell  to  cell  [11].  The  cytokines  IL-10 and TGF-β
secreted by iTregs can affect the cytokine production of CD4+ T cells. An increasing amount
of evidence indicates that the iTreg subtype is not a homogeneous group, but is divided into 2
subgroups, named Tr1 and Th3, depending on the secreted cytokines. Tr1 cells are thought to
secrete mainly IL-10, and Th3 cells secrete predominately TGF-β [8].
In recent years, new groups of Treg lymphocytes have been described: the first of the CD69+
phenotype with different expression of CD25, IL-10, and TGF-β, as well as another of the
CD4+NKG2D+ phenotype (NKG2D is an activating receptor expressed by all NK cells and
subsets of T lymphocytes). The latter play a significant immunosuppressive role, which is
apparently mediated by TGF-β and IL-10 [48].
The main function of Treg is to inhibit autoreactive T lymphocytes, so it is obvious that this
cell lineage defect will have an impact on the development of autoimmune diseases.
Relationships between CD4+ cell lineages
The differentiation and function of a particular CD4+ cell lineage is primarily dependent on
the presence of specific transcription factors [21–23]. Overexpression of T-bet during Th2
differentiation causes such cells to acquire competence to produce IFN-γ while, at the same
time, suppressing their capacity to produce IL-4 [16]. It has also been shown that IRF-4 (IFN
regulatory  factor-4,  which  is  important  in  Th2  differentiation,  also  plays  a  role  in  the
differentiation of Tregs controlling Th2. Similarly, it seems that STAT3 expression in Tregs is
necessary for the ability to suppress the pathological immune response by Th17 cells, which
require the presence of STAT3 for differentiation [14, 16]. Therefore, iTreg cells do not need
to be considered as one of the CD4 cell distinct fates (like Th1, Th2, and Th17), but as a
possible parallel line capable of separate regulatory targets [16].
In addition to transcription factors, important in the distinct differentiation of CD4 cells, the
cytokine environment plays a major role in cell differentiation. The dependence of the effects
of cytokines in individual CD4+ cell lineages on the differentiation and function of the other
cell lineages is the same as that of specific transcription factors from one group on another.
Cytokines that promote the differentiation of one cell subtype have an inhibitory effect on the
formation of another CD4+ cell subpopulation. For example, IL-4, which is necessary for Th2
lineage  differentiation,  is  a  factor  that  inhibits  Th1  development.  Consecutively,  Th1  is
formed in the presence of IL-12 and provided that IL-4 is neutralized [31]. IL-2 is a key
repressor of Th17 differentiation [34].
The essential meaning in the development of the immune response, including autoimmunity,
plays  the phenomenon of lymphocyte plasticity.  On account of this,  a specific subtype of
CD4+ cells can differentiate into cells of a different subpopulation. All of this occurs under
certain molecular conditions and in the presence of a specific set of cytokines. Thus, Th1
lymphocytes can transform into Th2 or Treg, Th2 into Th1, Th17, and Treg, Th17 into Th1,
Th2, or Treg, and Treg into Th1, Th2, or Th17 [14,49].
The importance of the Th and Treg lymphocyte subpopulations in AITD
Importance of Th1 and Th2 in AITD
Cytokines secreted by Th1 lymphocytes, with a significant pro-inflammatory effect, have a
clear influence on the development of autoimmune diseases, including AITD. Their main role
has  been  described  in  the  development  of  Hashimoto’s  thyroiditis;  however,  they  also
contribute in the development of Graves' Disease [50].
Hashimoto's disease is a classic example of a T-cell-mediated disease in which thyroid tissue
is destroyed by an inflammatory infiltrate consisting of CD8+ and CD4+ T cells, CD19+ B
cells,  macrophages,  and  plasma  cells  [8].  Activated  and  recruited  Th1  cells  may  be
responsible for enhanced IFN-γ and TNF-α production [10]. IFN-γ increases the expression of
MHC class I and II molecules, which significantly enhances the presentation of antigens to T
lymphocytes, and thus it stimulates their cytotoxicity. IFN-γ is also the strongest activator of
macrophages, which results in the intensification of their cytotoxicity and the destruction of
thyrocytes [8, 14].
Similarly to IFN-γ, TNF-α is one of the major cytokines in inflammation. TNF-α increases the
proliferation of T and B lymphocytes,  induces the secretion of many cytokines (including
IFN-γ), activates macrophages, and has a strong chemotactic effect [14]. In the presence of
increased amounts of IFN-γ and TNF-α, the thyroid cells secrete the chemokine CXCL10,
which intensifies  the  inflammatory infiltrate  and enhances  the autoimmune process.  High
levels of circulating CXCL10 have been shown in patients with AITD, mainly in HT, and
circulating CXCL10 is associated with the active phase of GD and GO [10].
It was discovered that the proportions of peripheral Th1 cells in CD4+ cells in patients with
severe HT were significantly higher than those with mild HT [7]. Moreover, it was found that
IFN-γ polymorphism, which is  related to  higher  IFN-γ,  is  more frequent  in  patients  with
severe HT than in those with mild HT [51].
Qiu Qin et al. proved that IFN-γ mRNA levels are higher in the peripheral blood of patients
with HT compared to healthy controls. Likewise, the mRNA levels of IFN-γ were higher in
patients with GD than in normal controls, but the difference was not significant [52].
In addition to the cytotoxic action of T lymphocytes,  the second mechanism of thyrocyte
destruction in HT is through death receptors, which allow transmission of the apoptotic signal
into the cell. One of the death receptors is the FAS receptor (CD95), the ligand of which is
FasL. The combination of Fas and FasL leads to programmed cell death (apoptosis). There is
evidence that thyrocytes from HT patients have the expression of both FAS and FAS ligand.
The third mechanism of thyrocyte destruction is through anti-Tg and anti-TPO antibodies.
The thyroid cells damaged by antibodies release cytokines such as IL-6, IL-1β, and IL-8,
which further stimulate the cytotoxic effects of lymphocytes. It is currently uncertain whether
the presence of the antibodies is the cause or the effect in the destruction of thyrocytes [8].
Certainly, anti-thyrotropin receptor antibodies (TRAbs) are the cause of the development of
Graves' disease. Therefore, this disease is classically described as a B cell-mediated disease.
The interaction between CD4+ T cells and auto-reactive B cells is required for the production
of  autoantibodies  against  the  TSHR.  Th2-mediated  immune  response  is  involved  in  this
process [53].
On the other hand, Th2 cells produce cytokines including IL-4, IL-5, and IL-10, which may
play a protective role in GD. It was shown above that in animal models IL-4 inhibits the
development of autoimmune diseases [7]. In Hashimoto's disease, Nanba et al. reported that
-590CC genotype in -590C/T polymorphism of the IL-4 gene, which is related to lower IL-4
production, was more frequent among severe HT patients compared to mild HT patients [54].
Similarly, in Graves' disease, IL-4 and IL-10 induce T-cell anergy, inhibit IFN-γ secretion and
CD8+ T cell cytotoxicity, and induce a phenotypic switch from Th1 to Th2 [53].
The imbalance of Th1 and Th2 is therefore very important in the development of both HT and
GD. The imbalance into Th1 increases the destruction of thyrocytes, gland atrophy, and the
development of hypothyroidism, while the imbalance into Th2 results in the appearance of
stimulating TRAb and causes hyperthyroidism and enlargement of the gland.
The importance of Th17 in AITD
Over the past 15 years, Th17 cells have emerged as crucial in the development of autoimmune
diseases [32, 55]. The IL-17 secreted by them stimulates the following (this family includes 6
interleukins described with letters from A to F, and IL-17E – also called IL-25): epithelial
cells,  fibroblasts,  and  macrophages  for  producing  inflammatory  mediators  such  as
chemokines,  cytokines  TNF-α,  IL-1β,  IL-6,  IL-8,  GM-CSF,  and  MCP-1  (monocyte
chemotactic  protein)  [35].  IL-17A and IL-17F are also key cytokines for the recruitment,
activation,  and migration  of  neutrophils  [56].  All  this  makes  Th17 cells  one  of  the  most
productive effector cells among T lymphocytes. Numerous studies have found an increased
percentage of Th17 cells and the cytokines of patients suffering from multiple autoimmune
diseases,  such  as  type  1  diabetes  [17],  inflammatory  bowel  disease  [57],  systemic  lupus
erythematosus, rheumatoid arthritis, multiple sclerosis, and psoriasis [58].
In the last  decade, an increased share of Th17 cells and the cytokines they secrete in the
course  of  autoimmune  thyroid  diseases  has  also  been  described  many  times  [7,59,60].
Researchers found enhanced levels of T cells synthesizing IL-17 and IL-22 in the peripheral
blood  from  AITD  patients,  mainly  in  those  with  HT.  Interestingly,  clearly  a  stronger
expression  of  IL-17  and  IL-22  was  detected  in  the  thyroid  glands  of  HT  patients  in
comparison with Graves’ disease patients or controls [60]. These studies indicate increased
involvement of Th17 cells in the pathogenesis of AITD, especially HT. Similar conclusions
can be drawn from the already cited research by Qui Qin et al., in which, besides Th1 cell
cytokines,  the  levels  of  IL-17A and  IL-23  in  thyroid  tissues  were  also  studied.  Tissue
expression of IL-17A and IL-23 was significantly higher in the HT group compared to the
control group, but it was not significantly increased in the GD group [52].
Scholars from Latvia also described the lack of a significant increase in the tissue expression
of IL-23 in the group of patients with GD compared to the control group. Tatjana Zake et al.
investigated  the  expression  of  IL-17 as  well  as  IL-23 and IL-1β in the  thyroid  tissue of
patients with HT and GD and patients with goitre as a control group. They found that the
expression level of IL-17 in thyrocytes was significantly higher in both HT and GO patients
than in colloid goitre patients, but IL-23 and IL-1β expression was increased only in the HT
group, not in the GD group [61].
Cui Li et al. in 2016 also estimated the presence of Th17 cells in AITD, dividing patients into
an HT (Hashimoto's thyroiditis) group, a GD (Graves 'disease) group, and a GO (Graves'
ophthalmopathy)  group.  They  found  that  compared  with  those  in  the  control  group,  the
percentage of CD4+IL-17+T cells and mRNA expression of its transcription factor RORγt
were higher  in peripheral  blood mononuclear  cells  of AITDs, also particularly in  the HT
subgroup. It is worth emphasising that in the GO group in patients with CAS above 4.5 the
percentage of Th17 was significantly increased compared to those with CAS below 4.5, which
indicates the degree of Th17 cell involvement in the inflammatory process depending on its
activity [62].
A study by Vitales-Noyola M et al., which we mention below, also confirmed the dependence
of Th17 cells on disease activity. They found increased levels of pathogenic Th17 cells in the
peripheral blood and thyroid glands of AITD patients, and the level of pathogenic Th17 cells
was dependent on the activity of AITD [63].
One  of  the  highly  pro-inflammatory  cytokines,  secreted  mainly  by  macrophages  and
monocytes after IL-17A simulation,  and secreted also by Th17 cells alone,  is IL-1β. This
cytokine simultaneously promotes (in addition to IL-6, IL-21, and IL-23) the formation of
Th17 lymphocytes [35]. Japanese researchers conducted a study on the polymorphism of the
gene encoding IL-1β. They found that the -31C/T polymorphism of the IL-1β gene, which is
related to the high producibility of IL-1β, was significantly more frequent in patients with
intractable  GD  than  in  those  with  GD  in  remission.  Additionally,  they  showed  that  the
proportion of IL-17-producing Th17 cells was higher in autoimmune thyroid disease patients
with the -31C/T polymorphism [64].
Li Zheng et al. proved that the expression of RORγt, IL-17 mRNA, and IL-17 protein levels
were markedly higher in GD patients group as compared with the control group. Interestingly,
high levels of IL-17 were found in the group of GD patients in hyperthyroidism and in the
euthyroid GD group. The same authors also investigated the expression of RORγt and the
levels of IL-17 mRNA and the protein after the administration of IL-23. The expression of
RORγt,  and levels of IL-17 mRNA and protein in the GD group with IL-23 dramatically
increased as compared with that in the GD group without IL-23 and in the control group
without IL-23 [65]. 
This study confirms the enhancement of proliferation and function of Th17 cells by IL-23,
and that  persistent  exposure to  IL-23 triggers  the  conversion  of  classical  Th17 cells  into
pathogenic Th17 cells [35].
The role of Th17 lymphocytes in the development of AITD is beyond doubt. An increasing
amount of evidence points to the participation of this group of cells in the development of
AITD, especially HT; however, the data concerning the participation in the pathogenesis of
GD are not equivocal. It seems that the role of Th17 in the development of GD is not as
crucial  as  in  the  development  of  HT,  where  pathogenic  Th17  cells  stimulated  by  IL-23
dominate among CD4+ cells.
The importance of Th9 and Th22 in AITD
In recent years, the involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid
arthritis [66], systemic lupus erythematosus, SLE [67], multiple sclerosis [68] and systemic
sclerosis [69] has been described. In patients with these diseases, increased serum IL-9 was
found [41].
Unfortunately,  there are few data on the involvement of Th9 cells  in the pathogenesis of
AITD. An interesting study was conducted by  Zivancevic-Simonovic et al.  in 2015. They
found that  papillary thyroid cancer  (PTC) patients  with HT produced significantly higher
concentrations of IL-9 than PTC patients without HT, which indicates the role of Th9 cells in
the pathogenesis of AITD [70]. There are also experimental studies of autoimmune diseases
with anti-IL-9 treatments [14,71].
We  know  more  about  the  involvement  of  Th22  cells  in  the  development  of  AITD.  As
mentioned  above,  Th22  cells  and  IL-22  have  been  considered  to  participate  in  the
pathogenesis of numerous autoimmune diseases. There are also some data on the involvement
of these cells in the development of AITD. Peng D et al. confirmed a higher frequency of IL-
22+CD+ T cells and higher concentrations of serum IL-22 in Graves's disease (GD) patients.
Moreover, they found a positive correlation between the percentages of Th22 in peripheral
blood with the concentrations of serum TRAb in GD patients [72].
Similar conclusions, but extended to patients with HT, were obtained by Vitales-Noyola et al.
in 2017. They found increased levels of Th22 cells in the peripheral blood of autoimmune
thyroid  disorder  patients  and  increased  presence  of  Th22  cells  in  the  thyroid  glands  of
Hashimoto's thyroiditis patients. Additionally, they found significant correlations between the
levels  of  Th22  cells  and  disease  activity,  disease  duration,  and  the  presence  of
ophthalmopathy [63].
The involvement of Th22 cells in the pathogenesis of AITD was also investigated by Bai et al.
The authors showed the level of circulating Th22 cells correlated with the level of serum IL-
22 in patients with HT and was significantly higher than in GD patients and healthy control
subjects [73].
Despite the undoubted role of Th22 lymphocytes in the pathogenesis of AITD, it seems that
their role is one of many and is not crucial for the development of AITD. Further research on
this group of cells is certainly needed.
The importance of Treg in AITD
The number of studies on the role and importance of Treg lymphocytes in the development of
AITD has clearly increased in  the last  decade.  As is  shown below, this  is  caused by the
growing interest in Th17 cells, which are crucial in the development of AITD, and whose
proliferation and function is tightly controlled by Treg lymphocytes.
It was assumed that in autoimmune diseases a reduced share of Tregs lymphocytes would be
observed,  which  have  an  immune  response  suppression  function.  However,  the  research
showed a slightly different, less expected result.
In murine models, depletion of CD4+CD25+ Tregs enhances the incidence and severity of HT
or GD. McLachlan et al.  proved that this depletion in genetically manipulated mice could
induce a shift from GD to HT [5]. In addition, prior transfer of CD4+CD25+ Treg cells into
mice could suppress Tg-induced experimental autoimmune thyroiditis (EAT) [35].
Similar results have been obtained in studies on humans. In the study by Cui Li et al., besides
examining Th17 cells, the authors also determined the number of Treg cells in patients with
AITD.  According to  their  results,  the  percentage  of  CD4+Foxp3+T cells  and the  mRNA
expression of its transcription factor Foxp3 were significantly decreased in peripheral blood
mononuclear cells (PBMCs) of AITD patients. However, a clear reduction of Treg cells was
observed only in the GD group, while in the HT and GO groups the difference compared to
the control group was less significant [62].
Diminished  levels  and  defective  suppressive  function  of  Tr1,  one  of  the  subtypes  of  T
regulatory  lymphocytes  in  patients  with  autoimmune  thyroiditis,  was  shown  by  Marlen
Vitales-Noyola et al. in 2018 [74].
Conversely, an increased presence of Treg cells in patients with AITD was already observed
in studies 2 decades ago. Monica Marazuela et al. explored the proportion of different T-cell
subsets with regulatory phenotype in the peripheral blood of patients with AITD and healthy
controls. They confirmed a significantly higher proportion of CD4+GITR+, CD4+Foxp3+,
CD4+CD69+, and CD4+ cells synthesizing IL-10 or TGF-β (respectively, Tr1 cells and Th3
cells)  in  patients  with  AITD.  The  scholars  also  found  an  increased  percentage  of  Treg
phenotype cells  in  thyroid tissue from patients  with autoimmune thyroiditis.  Interestingly,
they  assessed  the  suppressive  function  of  CD4+CD25+Treg  cells  using  different  cell
proliferation assays, and they found a significantly diminished regulatory activity of Treg cells
from  AITD  patients,  compared  with  controls  [75].  According  to  these  data,  the  clearly
increased presence of Treg lymphocytes in the thyroid of AITD patients is unable to inhibit
the  self-destruction  process,  which  indicates  an  impairment  of  Treg  function  in  the
pathogenesis of AITD.
Continuing  this  direction  of  research  in  2015  Rodríguez-Muñoz  et  al.  reached  similar
conclusions. This time, the presence of a new group of Treg lymphocytes with the phenotype
CD4+CD69+ and CD4+NKG2D+ secreting IL-10 and TGF-β in patients  with AITD was
investigated. They found a significantly increased percentage of these Tregs cells in peripheral
blood  and  thyroid  tissue  from  GD,  especially  with  GO  patients  compared  to  controls.
Importantly,  positive  correlation  between  GO  activity  and  CD4+CD69+IL-10+  or
CD4+CD69+IL-10+NKG2D+ cells  was  also  found.  Their  findings  suggest  that  increased
levels of Treg cells in AITD patients are probably unable to down-modulate the autoimmune
response [76].
Ziyi Chen et al. published last year a meta-analysis examining the percentage of peripheral
blood Tregs among CD4+ T cells in patients with autoimmune thyroid disease. They found
that the treatment status might affect the level of Tregs, so they conducted this meta-analysis
dividing AITD patients into untreated and treated groups. For example, among 10 studies of
untreated AITDs, 7 reported significantly decreased proportions of circulating Tregs in AITDs
compared to controls, 1 revealed non-significantly lower proportions of Tregs, and 2 studies
revealed increased proportions of Tregs. The result of this study indicated that the proportions
of circulating Tregs among CD4+ T cells of untreated AITDs were remarkably lower than in
healthy controls, but no significant difference was found in treated AITDs [46].
These  inconclusive  data  indicate  that  Tregs  lymphocytes  are  potentially  involved  in  the
pathogenesis of AITD, but their function appears to be different in HT and GD and dependent
on treatment status. The percentage of Tregs can change over the course of different stages of
treatment. Certainly, the suppressive capacity of Tregs is impaired in both GD and HT [35].
What seems to be the most important is that the involvement of Tregs in the development of
AITD should not be considered separately, but in relation to effector cells, mainly Th17 cells.
Th17/Treg balance as a basis for AITD development
The main role in the development of the autoimmune response is played by the Th17 and Th1
effector  cells  and,  on the other hand, the inhibitory Tregs lymphocytes.  Based on current
knowledge,  the  mutual  balance between Th17 cells  and Tregs  is  the  basis  for  the proper
functioning of the immune system, and the imbalance is the crucial cause of the development
of autoimmune diseases, including AITD. The deviated balance between Treg and Th17 with
an  orientation  to  Th17  in  an  animal  model  of  autoimmune  disease  and  in  most  human
autoimmune diseases was confirmed [77].
Several studies have shown an increased ratio of Th17/Treg in patients with AITD. Li et al.,
concluding a Th/Treg balance study in different AITD subtypes, found that increased Th17
lymphocytes  may play a  more  important  role  in  the  pathogenesis  of  HT and GO,  while
decreased Treg may be greatly involved in GD [62].
Qin et al. studied the involvement of Th17 and Treg cells in new-onset Graves' disease. They
detected  a  significantly  decreased  proportion  of  circulating  CD4+Foxp3+Treg  cells  and
reduced Foxp3 mRNA expression in patients with new-onset GD. The reduction of circulating
Treg cells may be due to the increased apoptosis of these cells found in previous studies by
Nakano et al. and Mao et al. The authors also confirmed that with the lower share of Treg
cells, there is an increased percentage of Th17 cells, and enhanced IL-17 and RORγt mRNA
expression level in patients with new-onset GD [78].
Moreover, a positive correlation was found between the proportion of circulating Th17 cells
and serum TRAb activity.  Comparing the occurrence of  Th17 and Treg cells,  researchers
found that the ratio of circulating Th17/Tregs was significantly higher in GD patients than in
healthy controls [78].
Whether it is the increased involvement of Th17 cells or the decreased participation of Treg
cells that causes the development of particular AITD subtypes, the imbalance of Th17/Tregs
seems to be most important in the development of AITD pathogenesis.
Mutual regulation between Th17 and Treg
Based on the knowledge that the imbalance between cytotoxic Th17 cells and regulatory T
cells is the foundation for the development of AITD, the factors regulating the correlation of
Th17 with Treg cells can be expected to play a key role.
The main modulator  of Th17/Treg balance is  transforming growth factor-β.  TGF-β in the
presence of IL-6, and IL-1β plays an important role in the differentiation of IL-17 producing T
cells from naive CD4+T cells [79]. Moreover, TGF-β not only leads to the development of the
Th17 cell lineage by inducing RORγt, but also inhibits the differentiation of Th1 and Th2
cells  [77,  79].  On  the  other  hand,  TGF-β  in  the  IL-2  environment  upregulates  Foxp3
expression and induces Treg cell differentiation [77]. The Tregs secrete TGF-β in addition to
IL-10; therefore, TGF-β promotes the formation of further Tregs, but TGF-β participates in
creating of the Th17 lineage only in the environment of proinflammatory cytokines such as
IL-6,  IL-1β, IL-23, etc.  [17, 77]. The effect of TGF-β on the possible expression of both
RORγt and Foxp3 indicates the presence of a common precursor cell RORγt+Foxp3+, which
in the environment of lineage-specific polarizing factors differentiates into Th17 or Tregs [16,
80].
Apart from TGF-β, the retinoic acid (vitamin A metabolite) and lipid inflammatory mediator,
such as leukotriene B4, LTB4 and prostaglandin E2, PGE2, as well as macrovesicles (MVs)
and SLAMF1 (signalling lymphocytic activation molecule family molecule family 1) have a
modulating effect on the Th17/Treg balance [35, 77]. Although this issue is not the scope of
our work, it shows the complexity of the process of maintain Th17/Treg balance.
CD4+ lymphocytes – plasticity and phenotype variability
All  CD4+  cells  have  the  capacity  to  change  plasticity  and  phenotype  (flexibility).
Interestingly, it seems that Th17 and Treg cells have the greatest possibility of changing the
phenotype. In the presence of IL-12, Th17 cell secreting IL-17 and IFN-γ (Th17/Th1 cell),
can be formed into a cell secreting only IFN-γ, called non-classic Th1. It is also known that
there are Th17 cells producing IL-4 (Th17/Th2 cell), besides IL-17 [81].
The common precursor RORγt+Foxp3+ cell,  playing the opposing role of Th17 and Treg
cells, is an example of the heterogeneity and potential variability of CD4+ cells [16]. It has
been shown that CD4+Foxp3+ cells can transform into IL-17 producing lymphocytes in the
environment of IL-2, IL-15, IL-21, and IL-23. An increased frequency of Foxp3+IL-17+ and
Foxp3+IFN-γ+ lymphocytes was also found in patients with autoimmune diseases [11]. The
possibility of converting immune suppression cells into pathogenic Th17 and vice versa is
extremely interesting from a practical point of view and can be used in treatment.
Conclusions
Autoimmune thyroid disease is one of the most common autoimmune diseases. Activation of
CD4+ cells  is the primary cause of both thyrocyte damage and the production of TSHR-
stimulating antibodies in autoimmune thyroid diseases. There is expanding knowledge on new
CD4+ T cell subtypes involved in the pathomechanism of AITD. The essential factor was the
shift from the Th1/Th2 balance paradigm to the fact that the Th17 and Treg imbalance is
crucial  for the development of AITD. In addition,  the mutual relationship between CD4+
cells, their phenotypic variability, and the comprehension of factors influencing the balance,
proliferation, and activation of CD4+ T cells is of great importance. Increasing knowledge of
the role and importance of CD4+ cells in the pathogenesis of AITD allows not only a better
understanding of the mechanisms of development of these diseases, but also helps to define
therapeutic targets.
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Figure  1.  Differentiation  and  features  of  Th  cell  subtypes.  IL —  interleukin;  LT-α  —
lymphotoxin; IFN-γ — interferon gamma; TGF-β — transforming growth factor beta; TNF-α
— tumour necrosis factor alpha
Figure 2. Plasticity of Th cells
Figure 3. Flexibility of Th cells
